Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Diroximel→

Diroximel Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1577222-14-0
Molecular formula
C11H13NO6
Molecular weight
255.22 g/mol
Drug class
Fumarate prodrugdisease-modifying therapy for multiple sclerosis
Mechanism of action
Rapidly hydrolysed to monomethyl fumarate (MMF), the same active metabolite formed from dimethyl fumarate. The mechanism of MMF in multiple sclerosis is not fully understood; Nrf2 pathway activation and modulation of inflammatory and oxidative-stress responses are proposed.
Indications / reported uses
  • Treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease, under the applicable product label.

Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211855s002lbl.pdf · https://www.ncbi.nlm.nih.gov/sites/books/NBK548484/

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Fumarate prodrug; disease-modifying therapy for multiple sclerosis

Mechanism of action

Rapidly hydrolysed to monomethyl fumarate (MMF), the same active metabolite formed from dimethyl fumarate. The mechanism of MMF in multiple sclerosis is not fully understood; Nrf2 pathway activation and modulation of inflammatory and oxidative-stress responses are proposed.

General use cases

  • Treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease, under the applicable product label.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Diroximel Environmental Risk Assessment (ERA) (the Diroximel ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.